Current stage-Stage III (Advanced) Posts on Medivizor
Navigation Menu

Current stage-Stage III (Advanced) Posts on Medivizor

Searching for patients to try a new therapy for advanced solid tumors.

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...

Read More

Evaluating a response-adapted treatment approach for pediatric patients with high-risk Hodgkin lymphoma

Posted by on Jun 30, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of pediatric patients with high-risk Hodgkin lymphoma (HL) after response-adapted treatment. This study concluded that PET scanning during treatment can help adapt further treatments and improve outcomes for these patients. Some background For most pediatric patients with HL, outcomes after...

Read More

Reviewing the risk of neutropenia after first-line treatment for advanced Hodgkin lymphoma

Posted by on Jun 25, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed the risk of patients with advanced Hodgkin lymphoma (HL) developing neutropenia after first-line treatment. This study concluded that this condition can be a serious complication for these patients. Some background The most commonly used frontline chemotherapy regimens for advanced HL are ABVD (doxorubicin,...

Read More

Searching for children with advanced Hodgkin lymphoma to test a new chemoimmunotherapy combination regimen

Posted by on May 24, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating the effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for children with advanced Hodgkin lymphoma (HL). The main outcome to be measured will be the number of patients who respond to treatment. The details Brentuximab vedotin is being tested to treat children who have advanced HL. Brentuximab...

Read More

Evaluating the impact of interim imaging on treatment outcomes for advanced cHL

Posted by on Mar 10, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the impact of interim functional imaging (IFI) on the outcomes of treatment for advanced classical Hodgkin lymphoma (cHL). This study found that patients with positive scan results were more likely to disease progression. Some background ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the...

Read More

Looking for patients with advanced stage Hodgkin lymphoma to test a treatment combination

Posted by on Jan 27, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is examining the effectiveness of a new treatment combination for advanced Hodgkin’s lymphoma (HL). The main outcomes to be measured will be the number of patients who experience side effects and response to treatment. This study is being conducted in New York, New Jersey, and Ohio, the United States. The details The...

Read More

Evaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma

Posted by on Jan 10, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...

Read More

Evaluating long-term outcomes of R-CHOP for advanced follicular lymphoma

Posted by on Nov 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) treatment for previously untreated patients with advanced follicular lymphoma (FL). This study concluded that R-CHOP is effective in patients with newly diagnosed advanced FL. Some background FL is the second most...

Read More

Long-term outcomes of radioimmunotherapy in patients with follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...

Read More

Evaluating rituximab maintenance therapy in patients with newly diagnosed follicular lymphoma

Posted by on Sep 6, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...

Read More

How safe and effective is R-CHOP as a first-line treatment for patients with FL in the long-term?

Posted by on Jan 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of R-CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, prednisone) to CHOP-RIT (CHOP followed by iodine-133-tositumomab, Bexxar) as a first-line treatment for follicular lymphoma (FL) patients. This study concluded that immunochemotherapy should remain the standard...

Read More

Is R-CHOP chemotherapy an effective first-line treatment for patients with grade 3 follicular lymphoma?

Posted by on Jan 7, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the long-term outcomes of patients with grade 3 follicular lymphoma (FLG3) who received first-line R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). The study concluded that this regimen is an effective first-line treatment for patients with FLG3, especially in those with less...

Read More